Propranolol Alleviates Cardiac Injury After Acute Catecholamine Infusion Through p38-MAPK Pathways

J Cardiovasc Pharmacol. 2024 Jul 1;84(1):110-117. doi: 10.1097/FJC.0000000000001571.

Abstract

Hypercatecholaminergic conditions are known to cause heart failure and cardiac fibrosis when severe. Although previous investigations have studied the effects of beta-blockade in experimental models of catecholaminergic states, the detailed benefits of beta-blockade in more realistic models of hyper-adrenergic states were less clear. In this study, we examined acute cardiac changes in rats with hyperacute catecholamine-induced heart failure with and without propranolol treatment. Male Sprague-Dawley rats (n = 12) underwent a 6-hour infusion of epinephrine and norepinephrine alone, with an additional propranolol bolus (1 mg/kg) at hour 1 (n = 6). Cardiac tissues were examined after 6 hours. Cardiac immunohistochemistry revealed significantly decreased expression of phosphorylated p-38 (left ventricle, P = 0.021; right ventricle, P = 0.021), with upregulation of reactive oxidative species and other profibrosis proteins, after catecholamine infusion alone. After 1 propranolol 1 mg/kg bolus, the levels of phosphorylated-p38 returned to levels comparable with sham (left ventricle, P = 0.021; right ventricle, P = 0.043), with additional findings including downregulation of the apoptotic pathway and profibrotic proteins. We conclude that catecholamine-induced heart failure exerts damage through the p-38 mitogen-activated protein kinase pathway and demonstrates profibrotic changes mediated by matrix metalloproteinase 9, alpha-smooth muscle actin, and fibroblast growth factor 23. Changes in these pathways attenuated acute catecholamine-induced heart failure after propranolol bolus 1 mg/kg. We conclude that propranolol bolus at 1 mg/kg is able to mediate the effects of catecholamine excess through the p-38 mitogen-activated protein kinase pathway, profibrosis, and extrinsic apoptosis pathway.

MeSH terms

  • Adrenergic beta-Antagonists* / administration & dosage
  • Adrenergic beta-Antagonists* / pharmacology
  • Animals
  • Apoptosis / drug effects
  • Catecholamines / metabolism
  • Disease Models, Animal
  • Epinephrine / administration & dosage
  • Epinephrine / toxicity
  • Fibrosis*
  • Heart Failure* / chemically induced
  • Heart Failure* / drug therapy
  • Heart Failure* / metabolism
  • Heart Failure* / pathology
  • Heart Failure* / physiopathology
  • Male
  • Myocardium / enzymology
  • Myocardium / metabolism
  • Myocardium / pathology
  • Norepinephrine* / metabolism
  • Phosphorylation
  • Propranolol* / pharmacology
  • Rats
  • Rats, Sprague-Dawley*
  • Reactive Oxygen Species / metabolism
  • p38 Mitogen-Activated Protein Kinases* / metabolism

Substances

  • Propranolol
  • p38 Mitogen-Activated Protein Kinases
  • Adrenergic beta-Antagonists
  • Norepinephrine
  • Epinephrine
  • Catecholamines
  • Reactive Oxygen Species